What's Happening?
Sun Life U.S. has released its annual report on high-cost medical claims, revealing that secondary health conditions, prolonged hospital stays, and specialty drugs are major contributors to claims exceeding $3 million. The report analyzed over 70,000
claims from more than 3,300 self-funded employers. It identified orthopedic/musculoskeletal (MSK) conditions, newborn care, and cancer as the most common conditions leading to high-cost claims. The report also noted a 46% increase in million-dollar claims from 2022 to 2026, with gene therapies and specialty drugs like Elevidys, used for Duchenne muscular dystrophy, being among the most expensive treatments.
Why It's Important?
The findings underscore the growing financial burden of healthcare on employers and the need for comprehensive health management strategies. As healthcare costs rise, driven by advanced treatments and complex conditions, employers face increased pressure to manage these expenses while ensuring employee health. The report suggests that addressing comorbidities and providing whole-person care can improve health outcomes and reduce costs. This is particularly relevant for conditions like cancer and MSK disorders, which are prevalent in the workforce and contribute significantly to disability claims. The insights from this report could influence policy decisions and healthcare strategies aimed at cost containment and improved patient care.
